Floatz logo

Pyrotinib

Portal Vein Thrombosis

RenJi HospitalSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

16 Active assets in the Portal Vein Thrombosis cohort.

Asset / SponsorPhaseRating
WARFARIN
Kafrelsheikh University
Phase 4BB
NADROPARIN
Shanghai Zhongshan Hospital
Phase 4BB
FLUOROURACILUM
First Hospital of China Medical University
Phase 2/3BB
Calcium folinate pentahydrate
First Hospital of China Medical University
Phase 2/3BB
Enoxaparin
Institute of Liver and Biliary Sciences, India
Phase 4BB

View all 22 →

Same molecule, other indications

Pyrotinib is also rated in:

Non Small Cell Lung CancerDormant
BB
Indicative ·
70 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
Small Cell Lung CancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →